Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Regeneron (IT:1REGN)
MILAN:1REGN
Holding IT:1REGN?
Track your performance easily
1REGN Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€723.00 - €1,083.50
Previous Close€925.6
Volume0.00
Average Volume (3M)3.00
Market Cap
€101.65B
Enterprise Value€95.27B
Total Cash (Recent Filing)$9.81B
Total Debt (Recent Filing)$2.70B
Price to Earnings (P/E)―
BetaN/A
Next Earnings
Oct 31, 2024EPS Estimate
€10.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding110,234,529
10 Day Avg. Volume7
30 Day Avg. Volume3
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)3.65
Price to Sales (P/S)8.28
Price to Cash Flow (P/CF)78.90
P/FCF Ratio160.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.06
Enterprise Value/Gross Profit8.43
Enterprise Value/Ebitda18.65
Forecast
1Y Price Target
€1,065.11Price Target Upside15.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering22
Regeneron News
Bulls Say, Bears Say
Bulls Say
Earnings GrowthDupixent is already driving approximately two-thirds of quarterly earnings, with potential for significant earnings growth.
FDA ApprovalFollowing FDA approval of Dupixent for use in patients with COPD, the model has been updated assuming peak revenue contribution of $2.5B.
Franchise StabilityThe Eylea HD launch is expected to outperform every quarter, leading to stability for the franchise and a slowing of market share gain from Vabysmo.
Bears Say
Earnings ImpactNear-term EPS numbers could see a significant impact if Amgen launches a biosimilar at risk, causing up to 10-15% downside to earnings per share.
Legal RulingThe court's decision to deny Regeneron's request for a preliminary injunction against Amgen's biosimilar Eylea creates uncertainty for the Eylea franchise.
Market CompetitionA biosimilar entrant could pose a substantial threat as roughly 80% of Eylea franchise revenues still come from the 2mg formulation.
---
Options Prices
Currently, No data available
---
Ownership Overview
1.94% Insiders
33.52% Mutual Funds
0.08% Other Institutional Investors
41.08% Public Companies and
Individual Investors
1REGN FAQ
What was Regeneron’s price range in the past 12 months?
Regeneron lowest stock price was €723.00 and its highest was €1083.50 in the past 12 months.
What is Regeneron’s market cap?
Currently, no data Available
When is Regeneron’s upcoming earnings report date?
Regeneron’s upcoming earnings report date is Oct 31, 2024 which is in 25 days.
How were Regeneron’s earnings last quarter?
Regeneron released its earnings results on Aug 01, 2024. The company reported €10.472 earnings per share for the quarter, beating the consensus estimate of €9.619 by €0.853.
Is Regeneron overvalued?
According to Wall Street analysts Regeneron’s price is currently Undervalued.
Does Regeneron pay dividends?
Regeneron does not currently pay dividends.
What is Regeneron’s EPS estimate?
Regeneron’s EPS estimate is €10.72.
How many shares outstanding does Regeneron have?
Regeneron has 108,417,380 shares outstanding.
What happened to Regeneron’s price movement after its last earnings report?
Regeneron reported an EPS of €10.472 in its last earnings report, beating expectations of €9.619. Following the earnings report the stock price went up 1.344%.
Which hedge fund is a major shareholder of Regeneron?
Among the largest hedge funds holding Regeneron’s share is Dodge & Cox. It holds Regeneron’s shares valued at 2B.
---
Regeneron Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€1,065.11 (15.07% Upside)
€1,065.11 (15.07% Upside)
Blogger Sentiment
Bullish
IT:1REGN Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $25.6M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
24.27%
12-Months-Change
Fundamentals
Return on Equity
16.55%
Trailing 12-Months
Asset Growth
17.71%
Trailing 12-Months
Company Description
Regeneron
Founded in 1988, Regeneron Pharmaceuticals, Inc. is a New York-based biotechnology company, which discovers, develops, manufactures, and commercializes medicines for the treatment of various medical conditions. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP.
---
1REGN Company Deck
---
1REGN Earnings Call
Q2 2024
0:00 / 0:00
---
1REGN Revenue Breakdown
44.87% EYLEA - U.S.
28.97% Sanofi
11.34% Bayer
4.11% Libtayo - U.S.
10.72% Other
---
1REGN Stock 12 Month Forecast
Average Price Target
€1,065.11
▲(15.07% Upside)
Technical Analysis
Regeneron
―
Amgen
―
BioMarin Pharmaceutical
―
Gilead Sciences
―
Vertex Pharmaceuticals
―
Best Analysts Covering 1REGN
1 Year
1 Year Success Rate
35/42 ratings generated profit
1 Year Average Return
+25.03%
assigned a buy rating 12 days ago
Copying Christopher Raymond's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +25.03% per trade.
---